StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report issued on Wednesday. The firm issued a sell rating on the medical research company’s stock.
OpGen Stock Performance
Shares of NASDAQ:OPGN opened at $1.75 on Wednesday. The stock’s fifty day simple moving average is $1.96 and its two-hundred day simple moving average is $3.17. OpGen has a 1-year low of $1.61 and a 1-year high of $11.20.
OpGen (NASDAQ:OPGN – Get Free Report) last released its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter.
Institutional Trading of OpGen
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Articles
- Five stocks we like better than OpGen
- Where to Find Earnings Call Transcripts
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Canada Bond Market Holiday: How to Invest and Trade
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.